xylyx

News

Researchers confirm successful rehabilitation and recovery of human donor lungs previously deemed unfit for transplant

A cross-disciplinary team of surgeons and bioengineers from Vanderbilt University, Columbia University, Stanford University, New York-Presbyterian Hospital, State University of New York Downstate Medical Center, and Xylyx Bio collaborated to develop a new technique called ‘xenogeneic cross-circulation’, which involves temporarily connecting a human donor lung to a live pig to support and resuscitate the human organ outside the body.

The Journal of Heart and Lung Transplantation recently published the peer-reviewed manuscript. The results showed the potential pf the technique to increase the number of organs available for transplant.

Xylyx Bio collaboration reveals new insights into tumor drug resistance

Researchers at the University of Illinois applied Xylyx Bio’s IN SITE Metastasis Kit to evaluate a cancer therapeutic. Molecular Cancer Research, a journal of the American Association for Cancer Research, recently published the peer-reviewed manuscript. The results showed that dietary interventions may increase the efficacy of treatment for breast cancer metastases.

Read the Publication!

Watch the Xylyx Bio Metastasis Webinar!

Xylyx Bio and Cell&Soft Announce positive initial results following Strategic Partnership to Develop Next-Generation in vitro Platforms to Accelerate Cancer Drug Discovery

New  York-based Xylyx Bio, a leader in predictive disease models and tissue-specific extracellular matrix (ECM) products, and Cell&Soft SAS, a French biotech company specializing in innovative soft cell culture plates, today announced positive preliminary results, reaching a key milestone in their partnership to develop more physiologically relevant in vitro cellular models for cell-based assays in oncology.

XYLYX BIO launches specialized contract R&D services that increase predictiveness in antifibrotic drug discovery

Xylyx Bio now offers specialized contract R&D services based on its highly predictive IN MATRICO™ platform. Xylyx Bio’s custom assays incorporate human disease-specific extracellular matrix (ECM) substrates combined with clinically relevant informatics to better represent human biology and reliably de-risk drug discovery through early efficacy signals that simultaneously reduce costs and development time.

XYLYX BIO releases highly physiologic 2D substrates for improved antifibrotic drug discovery

Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput screening and improve evaluation of efficacy of biopharmaceutical drug candidates for hard to treat fibrotic diseases such as IPF and NASH.

Webinar: Transforming lung fibrosis drug discovery with the IN MATRICO® Human Lung Fibrosis platform

Lung extracellular matrix (ECM) is implicated in the pathogenesis and progression of lung fibrosis. Current preclinical lung fibrosis models do not incorporate lung ECM, and therefore lack the defining part of the fibrotic lung disease environment.

In this webinar, we describe the paradigm shift in drug discovery from ‘in vitro’ to ‘in matrico’, and present our Human Lung Fibrosis platform for disease modeling and compound testing. Leveraging human fibrotic lung ECM and corresponding clinical data, the platform increases the relevance of cell-based assays and enables lung fibrosis modeling with clinical context to accelerate drug development.

  • Please fill out the form below to gain access to the video.
  • This field is for validation purposes and should be left unchanged.